Re: Carlsson SV, van den Bergh R. Prostate Cancer Screening: The Population Benefit Outweighs the Harm (Pro). Eur Urol Focus. 2026 Sep 16:S2405-4569(26)00197-5 doi:10.1016/j.euf.2026.09.001
Re: Carlsson SV, van den Bergh R. Prostate Cancer Screening: The Population Benefit Outweighs the Harm (Pro). Eur Urol Focus. 2026 Sep 16:S2405-4569(26)00197-5 doi:10.1016/j.euf.2026.09.001. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456926002695?dgcid=rss_sd_all
Re: Carlsson SV, van den Bergh R. Prostate Cancer Screening: The Population Benefit Outweighs the Harm (Pro). Eur Urol Focus. 2026 Sep 16:S2405-4569(26)00197-5 doi:10.1016/j.euf.2026.09.001. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456926002695?dgcid=rss_sd_all
“Re: Carlsson SV, van den Bergh R. Prostate Cancer Screening: The Population Benefit Outweighs the Harm (Pro). Eur Urol Focus. 2026 Sep 16:S2405-4569(26)00197-5 doi:10.1016/j.euf.2026.09.001.” European Urology Focus.
@article{article100147,
title = {Re: Carlsson SV, van den Bergh R. Prostate Cancer Screening: The Population Benefit Outweighs the Harm (Pro). Eur Urol Focus. 2026 Sep 16:S2405-4569(26)00197-5 doi:10.1016/j.euf.2026.09.001},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456926002695?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...